Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating yesterday.Stay Ahead of the ...

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company’s ambitions to advance its portfolio of next generation Targeted Glue™ protein degrader ...

Scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Kymera Therapeutics (KYMR – Research Report).

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by ...

In 2023, scientists in the joint School of Engineering and School of Life Sciences Laboratory of Protein Design and Immunoengineering ( LPDI ), led by ...

Request To Download Free Sample of This Strategic Report @ The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global ...

Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and ...

SiliconRepublic.com details the 25 of the most intriguing tech start-ups based in Europe that are worth monitoring in 2025.

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew ...